Hostname: page-component-745bb68f8f-b6zl4 Total loading time: 0 Render date: 2025-02-02T23:35:42.735Z Has data issue: false hasContentIssue false
  • English
  • Français

Canadian Guidelines for Intravenous Thrombolytic Treatment in Acute Stroke: A Consensus Statement of The Canadian Stroke Consortium

Published online by Cambridge University Press:  18 September 2015

J.W Norris ,
A. Buchan ,
R. Cote ,
V. Hachinski ,
S.J. Phillips ,
A. Shuaib ,
F. Silver ,
D. Simard  and
P. Teal
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The thromobolytic drug, tissue plasminogen activator (tPA) has been approved in the United States for the treatment of acute ischemic stroke amid controversy and concern about the balance of risk and benefit. The Canadian Stroke Consortium (CSC), a national network of neurologists who collaborate on joint projects in stroke medicine, including clinical trials and consensus statements, has developed guidelines for the use of tPA in Canada.

Methods and Results:

The CSC Board of Directors wrote a preliminary report based on existing publications, including randomized drug trials and the report of a special committee struck by the Stroke Council of the American Heart Association. This draft was circulated to the CSC membership-at-large for suggestions or amendments, to produce this final draft.

Conclusions:

The present guidelines have been devised to represent a Canadian viewpoint of management. The Health Protection Branch of the Ministry of Health of Canada has not yet produced an evaluation. Further modification of these guidelines may be necessary when more data from clinical trials and experience with the drug become available.

Type
Neurological Practice
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 3 , August 1998 , pp. 257 - 259
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–150.CrossRefGoogle Scholar
2.The Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995; 346: 1509–1514.CrossRefGoogle Scholar
3.Donnan, GA, Davis, SM, Chambers, BR, et al. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA 1996; 276: 961–966.CrossRefGoogle ScholarPubMed
4.Hacke, W, Kaste, M, Fieschi, C, et al. for The European CooperativeAcute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017–1025.CrossRefGoogle ScholarPubMed
5.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.CrossRefGoogle Scholar
6.Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients With Acute Ischemic Stroke. Stroke Council, American Heart Association. Stroke 1996; 27: 1711–1718.Google Scholar
7.European Strategies for Early Intervention in Stroke: A Report of an Ad Hoc Consensus Group Meeting. Cerebrovascular Dis 1996; 6: 315–324.Google Scholar
8.Wardlaw, JM, Warlow, CP, Counsell, C. Systematic review of evidence on thrombolytic therapy for acute ischemic stroke. Lancet 1997; 350: 607–614.CrossRefGoogle Scholar